Lineagen Overview
- Year Founded
-
2006
- Status
-
Acquired/Merged
- Employees
-
125
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$7.14M
- Investors
-
1
Lineagen General Information
Description
Developer of a genetic testing technology designed for children with neurodevelopmental disorders. The company's technology uses chromosomal microarray (CMA) testing technology, which can detect hundreds of genetic conditions and is recommended as the first-tier test for global developmental delay according to nationally accepted guidelines, enabling physicians to personalize medical management for individuals with developmental delay and an autism spectrum disorder.
Contact Information
Website
www.lineagen.comCorporate Office
- 2677 East Parleys Way
- Salt Lake City, UT 84109
- United States
Corporate Office
- 2677 East Parleys Way
- Salt Lake City, UT 84109
- United States
Lineagen Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 16. Merger/Acquisition | 21-Aug-2020 | $7.14M | Completed | Generating Revenue | ||
| 15. Debt - PPP | 13-Apr-2020 | Completed | Generating Revenue | |||
| 14. Debt - General | 09-Oct-2019 | Completed | Generating Revenue | |||
| 13. Later Stage VC | 23-May-2019 | Completed | Generating Revenue | |||
| 12. Later Stage VC (Series C1) | 25-Jan-2017 | Completed | Generating Revenue | |||
| 11. Later Stage VC (Series C1) | 09-Jan-2015 | Completed | Generating Revenue | |||
| 10. Later Stage VC (Series C) | 22-Nov-2013 | Completed | Generating Revenue | |||
| 9. Later Stage VC (Series B) | 24-Apr-2013 | Completed | Generating Revenue | |||
| 8. Grant | 15-Dec-2011 | $622K | $24.8M | Completed | Generating Revenue | |
| 7. Later Stage VC (Series B) | 04-Jan-2011 | $5M | $24.8M | Completed | Generating Revenue |
Lineagen Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C1 | ||||||||
| Series B | ||||||||
| Series A | 1,000 | $0.001000 | 8% | $1 | $1 | 1x | $1 | 0% |
Lineagen Comparisons
Industry
Financing
Details
Lineagen Competitors (10)
One of Lineagen’s 10 competitors is Cepheid, a Formerly VC-backed company based in Sunnyvale, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Cepheid | Formerly VC-backed | Sunnyvale, CA | ||||
| ChromaCode | Venture Capital-Backed | Carlsbad, CA | ||||
| New World Technologies | Corporation | New York, NY | ||||
| HemoCue | Corporate Backed or Acquired | Ängelholm, Sweden | ||||
| Ambry Genetics | Formerly PE-Backed | Aliso Viejo, CA |
Lineagen Patents
Lineagen Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20190247326-A1 | Identification of seizure susceptibility region in wolf-hirschhorn syndrome and treatment thereof | Inactive | 20-Sep-2016 | ||
| US-20210212960-A1 | Identification of seizure susceptibility region in wolf-hirschhorn syndrome and treatment thereof | Inactive | 20-Sep-2016 | ||
| WO-2018057484-A1 | Identification of seizure susceptibility region in wolf-hirschhorn syndrome and treatment thereof | Inactive | 20-Sep-2016 | ||
| WO-2017210456-A1 | Systems, devices and methods for improved analysis and storage of genotypic and phenotypic data | Inactive | 01-Jun-2016 | ||
| US-20170037475-A1 | Genetic markers associated with asd and other childhood developmental delay disorders | Inactive | 09-Apr-2014 | C12Q1/6883 |
Lineagen Signals
Lineagen Former Investors (17)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Archipel Capital | Venture Capital | Minority | ||
| Hatteras Investment Partners | Fund of Funds | Minority | ||
| HealthQuest Capital | Growth/Expansion | Minority | ||
| Kickstart (US) | Venture Capital | Minority | ||
| Kinect Capital | Accelerator/Incubator |
Lineagen FAQs
-
When was Lineagen founded?
Lineagen was founded in 2006.
-
Where is Lineagen headquartered?
Lineagen is headquartered in Salt Lake City, UT.
-
What is the size of Lineagen?
Lineagen has 125 total employees.
-
What industry is Lineagen in?
Lineagen’s primary industry is Other Healthcare Technology Systems.
-
Is Lineagen a private or public company?
Lineagen is a Private company.
-
What is the current valuation of Lineagen?
The current valuation of Lineagen is .
-
What is Lineagen’s current revenue?
The current revenue for Lineagen is .
-
How much funding has Lineagen raised over time?
Lineagen has raised $53.4M.
-
Who are Lineagen’s investors?
Archipel Capital, Hatteras Investment Partners, HealthQuest Capital, Kickstart (US), and Kinect Capital are 5 of 17 investors who have invested in Lineagen.
-
Who are Lineagen’s competitors?
Cepheid, ChromaCode, New World Technologies, HemoCue, and Ambry Genetics are some of the 10 competitors of Lineagen.
-
When was Lineagen acquired?
Lineagen was acquired on 21-Aug-2020.
-
Who acquired Lineagen?
Lineagen was acquired by Bionano Genomics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process